Clinical trials
-
Advanced Lung cancer: BNT327 with Docetaxel – BNT327-07
Read more: Advanced Lung cancer: BNT327 with Docetaxel – BNT327-07A Phase II, multisite, open-label, single arm trial of BNT327 in combination with docetaxel in second-line stage IV non-small cell lung cancer (NSCLC) following chemo-immunotherapy.
-
Advanced lung cancer (1st line): BNT327 combo – Rosetta Lung-02 BNT327-06
Read more: Advanced lung cancer (1st line): BNT327 combo – Rosetta Lung-02 BNT327-06A Phase II/III, multisite, randomized master protocol for a global trial of BNT327 in combination with chemotherapy and other investigational agents in first-line non-small cell lung cancer
-
Advanced Lung cancer BNT 326-02: BNT326 with BNT327
Read more: Advanced Lung cancer BNT 326-02: BNT326 with BNT327A Phase Ib/II, multi-site, open-label, dose finding trial to evaluate the safety, efficacy, and pharmacokinetics of BNT326 in combination with BNT327 in participants with advanced non-small cell lung cancer (NSCLC).
-
Advanced Solid Tumours: ARC-101 in CLDN6 positive
Read more: Advanced Solid Tumours: ARC-101 in CLDN6 positiveA Phase 1 Study of ARC101 in Advanced Solid Tumors
-
Endometrial cancer HER2+: BNT323-01 / DB-1303 versus chemotherapy
Read more: Endometrial cancer HER2+: BNT323-01 / DB-1303 versus chemotherapyA Phase III, randomized, multi-site, open-label trial of BNT323/DB-1303 versus investigator’s choice of chemotherapy in previously treated patients with HER2-expressing recurrent endometrial cancer